ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-21

Price

$114.98

-0.02%

Score13.5Top Tier

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.8xvs 20d avg

Analysis

Arcellx (ACLX) is currently trading as a classic merger arbitrage play following Gilead Sciences' definitive agreement to acquire the company for $115 per share in cash plus a $5 Contingent Value Right (CVR). The stock's current price of $114.98 perfectly reflects this cash offer, explaining the ultra-low 1.1% realized volatility and the QUIET_STORM and STEADY_CLIMB technical signals as the price remains pinned. Furthermore, the broader RISK_ON macro regime and exceptionally low credit spreads (0.81%) provide a highly supportive environment for M&A finalization, giving institutional investors high conviction that the deal will close without financing or systemic hurdles in Q2 2026.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUEBARGAIN HUNTER

Key Takeaways

Merger Arb Pin: ACLX is trading at $114.98, tightly pinned to Gilead's $115 upfront cash acquisition offer, capping immediate directional upside.
CVR Upside: Additional long-term upside is entirely tethered to the $5 Contingent Value Right, which pays out if anito-cel hits $6B in cumulative sales by the end of 2029.
Deal Risk: The primary downside risk is an unexpected regulatory block or deal collapse before the expected Q2 2026 close, which would cause a severe downward repricing.

← Back to 2026-04-21 View Full ACLX History →Yahoo Finance &nearr;